PF-06651600 - JAK 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第1頁
PF-06651600 - JAK 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第2頁
PF-06651600 - JAK 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第3頁
PF-06651600 - JAK 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第4頁
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進行舉報或認(rèn)領(lǐng)

文檔簡介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEPF-06651600Cat. No.: HY-100754CAS No.: 1792180-81-4分式: CHNO分量: 285.34作靶點: JAK作通路: Epigenetics; JAK/STAT Signaling; Stem Cell/Wnt儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 150 mg/mL (52

2、5.69 mM; Need ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.5046 mL 17.5230 mL 35.0459 mL5 mM 0.7009 mL 3.5046 mL 7.0092 mL10 mM 0.3505 mL 1.7523 mL 3.5046 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。體內(nèi)實驗 請根據(jù)您的實驗動物和給藥式選擇適當(dāng)?shù)娜芙獍?,配制前請先配制澄清的儲備液,再依次添加助溶?為保證實驗結(jié)果的可靠性,體內(nèi)實驗的作

3、液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄清的儲備液可以根據(jù)儲存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (8.76 mM); Clear solution2. 請依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (8.76 mM); Clear solutionBIOLOGICAL ACTIVITY1/3 Master of Small Molecules 您邊的抑制劑

4、師www.MedChemE物活性 PF-06651600種強效的 JAK3 選擇性抑制劑, 其 IC50 值為 33.1 nM。IC50 & Target JAK333.1 nM (IC50)體外研究 PF-06651600 is a potent JAK3-selective inhibitor which can inhibit the JAK3 kinase activity with an IC50 of33.1 nM but without activity (IC5010000 nM) against JAK1, JAK2, and TYK2. PF-06651600 inhibi

5、ts thephosphorylation of STAT5 elicited by IL-2, IL-4, IL-7, and IL-15 with IC50 values of 244, 340, 407, and 266nM, respectively. PF-06651600 also inhibits the phosphorylation of STAT3 elicited by IL-21 with an IC50 of355 nM. Functional assessment in T-cell differentiation assays demonstrate that P

6、F-06651600 suppressesTh1 and Th17 differentiation as measured by IFN, after 5 days under Th1 conditions, and IL-17 production,after 6 days under Th17 conditions, with IC50 values of 30 nM and 167 nM, respectively. PF-06651600 alsosuppresses Th1 and Th17 function as measured by the inhibition of IFN

7、production (IC50=48 nM) and IL-17production (IC50=269 nM) in cells that have been previously differentiated and rested before being treatedwith PF-06651600 1.體內(nèi)研究 In the rat adjuvant-induced arthritis (AIA) model, PF-06651600 reduces paw swelling with an unbound EC50of 169 nM. Similarly, PF-06651600

8、 significantly reduces disease severity in the experimental autoimmuneencephalomyelitis (EAE) mouse model when dosed either therapeutically at 30 or 100 mg/kg orprophylactically at 20 and 60 mg/kg. The efficacy of PF-06651600 in these two rodent models ofinflammatory and autoimmune diseases illustra

9、tes that JAK3-selective inhibition can be sufficient to havedisease modifying effects in human diseases 1.PROTOCOLCell Assay 1 To study the effect of PF-06651600 on Th17 cells post differentiation, skewed Th17 cells are washed, restedwith medium for overnight and resuspended in medium containing the

10、 same concentrations of cytokines asduring skewing but without anti-CD3 or anti-CD28 antibodies, in the presence of PF-06651600 at 10 differentconcentrations for 2 additional days. On Day 9, supernatant is harvested from each well and IL-17A isdetermined 1.MCE has not independently confirmed the acc

11、uracy of these methods. They are for reference only.Animal The effect of JAK3 inhibition by PF-06651600 is evaluated in vivo using a therapeutic dosing paradigm in aAdministration 1 rat adjuvant-induced arthritis. When individual hind paw volume measurements indicate an increase of 0.2mL (or greater

12、) in a single hind paw, animals are randomly assigned to a treatment group. Daily treatmentwith PF-06651600 is administered via oral gavage. Treatment groups for Experiment 1 are: 80, 15, or 6mg/kg of PF-06651600 or vehicle (2% Tween 80/0.5% methylcellulose/deionized water). Treatment groupsfor Expe

13、riment 2 are: 30, 10, and 3 mg/kg of PF-06651600 or vehicle (0.5% methylcellulose/de-ionizedwater/1 mEQ hydrochloric acid). Treatment groups for Experiment 3 are: 10, 1, 0.3 and 0.1 mg/kg of PF-06651600 or vehicle (0.5% methylcellulose/de-ionized water/1 mEQ hydrochloric acid). Treatment continuesfo

14、r 7 days 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES2/3 Master of Small Molecules 您邊的抑制劑師www.MedChemE1. Telliez JB, et al. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. ACS Chem Biol. 2016 Dec 16;11(12

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論